Astellas Beats Rivals To Japan HIF-PHI Market As Roxadustat Launched

 
• By Ian Haydock

Astellas becomes first to market in Japan in new class of oral anemia drugs, beating multiple rivals in a sector set to see strong growth but also fierce competition.

Rocket takes off from the hand of the businessman. Concept of start up.
Roxadustat Launches First Salvo In Japan HIF-PHI Battle • Source: Shutterstock

More from Japan

More from Focus On Asia